Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Peregrine Says Lung Cancer Trial Data Erroneous - Quick Facts

RELATED NEWS
Trade PPHM now with 

Peregrine Pharmaceuticals Inc. (PPHM: Quote) announced that during the course of preparing for an end-of-phase II meeting with regulatory authorities and following recent data announcements from its randomized, double-blind placebo-controlled Phase II trial of bavituximab in second-line non-small cell lung cancer, it discovered major discrepancies between some patient sample test results and patient treatment code assignments.

The company stated that due to the double-blind nature of the trial, it was not permitted to have access to either patient group assignments or related product coding information.

As part of the trial's execution, Peregrine contracted with independent third-party contractors to execute treatment group assignments and oversee clinical trial material coding and distribution according to established procedures. A subsequent review of information has determined that the source of these discrepancies appear to have been associated with the independent third-party contracted to code and distribute investigational drug product.

Click here to receive FREE breaking news email alerts for Peregrine Pharmaceuticals Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Initial jobless claims in the U.S. fell by slightly more than expected in the week ended August 16th, according to a report released by the Labor Department on Thursday. The Labor Department said jobless claims dropped to 298,000, a decrease of 14,000 from the previous week's revised level of 312,000. After ending the previous session mostly higher, stocks may see some further upside in early trading on Thursday. The major index futures are currently pointing to a higher open for the markets, with the Dow futures up by 36 points. U.K. retail sales growth eased in July as auto fuel turnover declined markedly from June, official data showed Thursday. The public sector finance figures were also weaker than expected in July despite economic rebound. Including auto fuel, retail sales volume grew 0.1 percent in July from a month ago, slower than the revised 0.2 percent increase in June, the Office for National Statistics said.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.